-
Product Insights
Akvilon Grp – Akvilon Yanino Comfort Class Residential Complex – Leningradskaya Oblast’
The Akvilon Grp – Akvilon Yanino Comfort Class Residential Complex – Leningradskaya Oblast' involves the construction of the Akvilon Yanino comfort class residential complex on a 66,000m2 area in Vsevolozhsk, Leningradskaya Oblast, Russia. Equip yourself with the essential tools needed to make informed and profitable decisions with our Akvilon Grp – Akvilon Yanino Comfort Class Residential Complex – Leningradskaya Oblast' report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furosemide in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furosemide in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DM-919 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DM-919 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DM-919 in Solid Tumor Drug Details: DM-919 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799933 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799933 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799933 in Metastatic Melanoma Drug Details: PF-07799933 (ARRY-440) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-619 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Prostate Cancer Drug Details: CLN-619 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-619 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Colon Cancer Drug Details: CLN-619 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-619 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Endometrial Cancer Drug Details: CLN-619 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remodulin in Ischemia Reperfusion Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remodulin in Ischemia Reperfusion Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remodulin in Ischemia Reperfusion Injury Drug Details: Treprostinil (Remodulin, Treprost)...
-
Analyst Opinions
NewUnited States (US) Wealth Management – High Net Worth (HNW) Investors
US Wealth Management Report Overview In the US, men dominate the High Net Worth (HNW) space, accounting for more than 82% of HNWs. The situation is slowly evolving, however, with female HNW investors becoming an increasingly attractive target segment. The US wealth management market report analyzes the investment preferences, service requirements, and portfolio allocation of US HNW investors. The report is based on GlobalData’s proprietary Global Wealth Managers Survey. Key Investment Preferences ·      Advisory Asset Management ·      Automated Investment Services...
-
Product Insights
NewNet Present Value Model: Sanofi’s INBRX-101
Empower your strategies with our Net Present Value Model: Sanofi's INBRX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based...